<clinical_study>
<study_id>
<org_name>
  GSK
</org_name>
<org_full_name>
  GlaxoSmithKline
</org_full_name>
<org_study_id>
  CXA30007
</org_study_id>
<nct_id>
  NCT00120900
</nct_id>
</study_id>
<brief_title>
<textblock>
  Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The Knee
</textblock>
</brief_title>
<official_title>
<textblock>
  See Detailed Description
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  GlaxoSmithKline
</agency>
</lead_sponsor>
</study_sponsor>
<resp_party>
<resp_party_type>
  Sponsor
</resp_party_type>
</resp_party>
<oversight_info>
<regulatory_authority>
  United States: Food and Drug Administration
</regulatory_authority>
</oversight_info>
<brief_summary>
<textblock>
  This study was designed to evaluate the effectiveness of GW406381 (a COX-2 inhibitor) in treating the signs and symptoms of osteoarthritis of the knee.
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
  A Phase III, 12-week, Multicentre, Double-blind, Double-dummy, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group study to investigate the Efficacy and Safety of GW406381 1mg, 5mg, 10mg, 25mg and 50mg administered orally once daily, in adults with Osteoarthritis of the knee (CXA30007).
</textblock>
</detailed_descr>
<status_block>
<status>
  Completed
</status>
<date>
2013-06 
</date>
</status_block>
<start_date>
<date>
  2005-05
</date>
</start_date>
<phase_block>
<phase>
  Phase 3
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Randomized
</design>
<design>
  Double Blind
</design>
<design>
  Parallel Assignment
</design>
<design>
  Safety/Efficacy Study
</design>
<primary_outcome>
<measure>
  Change in OA symptoms at week 12 as measured by scores on subject-completed questionnaires on pain, daily activities and global assessment
</measure>
<time_frame>
</time_frame>
</primary_outcome>
<secondary_outcome>
<measure>
  Change in OA symptoms as measured by subject and physician-completed questionnaires at each scheduled visit.  Percentage of responders, subjects discontinuing due to lack of efficacy, use of rescue medication and health-related quality of life.
</measure>
<time_frame>
</time_frame>
</secondary_outcome>
<enrollment>
  1113
</enrollment>
<condition>
  Osteoarthritis, Knee
</condition>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  GW406381
</primary_name>
<description>
<textblock>
</textblock>
</description>
<other_name>
  GW406381
</other_name>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion criteria:
 
    - Subjects have a primary diagnosis of osteoarthritis of the knee with symptom duration of at least 3 months.
 
    - Use pain medication, such as a COX-2 inhibitor or NSAID (non-steroidal anti-inflammatory drug) at least 5 days per week.  
 
  Exclusion criteria:
 
    - History of hypersensitivity or intolerance to pain medications.
 
    - History of gastroduodenal perforations and/or obstructions.
 
    - History of upper GI (gastrointestinal) ulceration within the previous 6 months.
 
    - History of upper or lower GI bleeding within the previous year.
 
    - History of inflammatory bowel disease.
 
    - Currently take sucralfate or misoprostol.
 
    - Currently taking aspirin daily for the heart.
 
    - Other restrictions around the use medications apply and would need to be discussed.
 
    - History of coronary artery disease, (angina, MI) or surgery.
 
    - History of congestive heart failure or renal artery stenosis.
 
    - History of stroke or transient ischemic attack.
 
    - History of uncontrolled hypertension.
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Both
</gender>
<minimum_age>
  40 Years
</minimum_age>
<maximum_age>
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Director
</role>
<name>
  GSK Clinical Trials
</name>
<affiliation>
<agency>
  GlaxoSmithKline
</agency>
</affiliation>
</investigator>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
  Ishoj
</city>
<state>
</state>
<zip>
  2635
</zip>
<country>
  Denmark
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
Anyang-Si 
</city>
<state>
</state>
<zip>
431-070 
</zip>
<country>
  Korea, Republic of
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
  Seoul
</city>
<state>
</state>
<zip>
  138-736
</zip>
<country>
  Korea, Republic of
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
  Seoul
</city>
<state>
</state>
<zip>
110-744 
</zip>
<country>
  Korea, Republic of
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
  Seoul
</city>
<state>
</state>
<zip>
133-792 
</zip>
<country>
  Korea, Republic of
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
  Seoul
</city>
<state>
</state>
<zip>
135-710 
</zip>
<country>
  Korea, Republic of
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
  Seoul
</city>
<state>
</state>
<zip>
</zip>
<country>
  Korea, Republic of
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
Daegu 
</city>
<state>
</state>
<zip>
705-718 
</zip>
<country>
  Korea, Republic of
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
  Seoul
</city>
<state>
</state>
<zip>
120-752 
</zip>
<country>
  Korea, Republic of
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
 Heerlen 
</city>
<state>
</state>
<zip>
6416 EG 
</zip>
<country>
  Netherlands
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
  De Bilt
</city>
<state>
</state>
<zip>
  3731 DN
</zip>
<country>
  Netherlands
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
 Ewijk 
</city>
<state>
</state>
<zip>
6644 CL 
</zip>
<country>
  Netherlands
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
 De Bilt 
</city>
<state>
</state>
<zip>
3731 DN 
</zip>
<country>
  Netherlands
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
 De Bilt 
</city>
<state>
</state>
<zip>
3731 DN 
</zip>
<country>
  Netherlands
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
Oslo 
</city>
<state>
</state>
<zip>
N-0370 
</zip>
<country>
  Norway
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
Lier 
</city>
<state>
</state>
<zip>
3400 
</zip>
<country>
  Norway
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
H&#248;nefoss 
</city>
<state>
</state>
<zip>
N-3515 
</zip>
<country>
  Norway
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
  Bergen
</city>
<state>
</state>
<zip>
  N-5068
</zip>
<country>
  Norway
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
Hamar 
</city>
<state>
</state>
<zip>
2317 
</zip>
<country>
  Norway
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
  San Juan
</city>
<state>
</state>
<zip>
</zip>
<country>
  Spain
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<location>
<facility>
<name>
  GSK Investigational Site
</name>
<address>
<city>
  Helsingborg
</city>
<state>
</state>
<zip>
  SE-252 78
</zip>
<country>
  Sweden
</country>
</address>
</facility>
<status>
  Completed
</status>
<contact>
<name>
  US GSK Clinical Trials Call Center
</name>
<phone>
  877-379-3718
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
<contact>
<name>
  EU GSK Clinical Trials Call Center
</name>
<phone>
  +44 (0) 20 8990 4466
</phone>
<phone_ext>
</phone_ext>
<email>
  GSKClinicalSupportHD@gsk.com
</email>
</contact>
</location>
<keyword>
  COX-2 inhibitor
</keyword>
<keyword>
  Knee osteoarthritis
</keyword>
<initial_release_date>
  2005-06-30
</initial_release_date>
<last_release_date>
2013-07-11 
</last_release_date>
<init_disposition_release_date>
</init_disposition_release_date>
<init_results_release_date>
</init_results_release_date>
</clinical_study>
